Cell cycle alterations and lung cancer

Histology and Histopathology

Volumn 21, Issue 4-6, 2006, Pages 423-435

  Vincenzi, Bruno ^a,b,c   Schiavon, G ^a,b   Silletta, M ^a,b   Santini, D ^a,b   Perrone, G ^a,b   Di Marino, M ^a,b   Angeletti, S ^a,b   Baldi, A ^a,b   Tonini, G ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Department of Medical Oncology ^*  (Italy)

Author keywords

Cell cycle; Lung cancer; Oncogenes; Oncosuppressors

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; K RAS PROTEIN; ONCOPROTEIN; PROTEIN P107; PROTEIN P130; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; THYROID HORMONE RECEPTOR; TUMOR SUPPRESSOR PROTEIN; CYCLIN DEPENDENT KINASE;

CANCER RESEARCH; CELL CYCLE REGULATION; CLINICAL PRACTICE; DATA ANALYSIS; GENE EXPRESSION; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL LITERATURE; MOLECULAR BIOLOGY; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; PATHOGENESIS; PHENOTYPE; PROGNOSIS; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; CELL CYCLE; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTO ONCOGENE; SMALL CELL CARCINOMA; TUMOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENES, P16; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; ONCOGENES; PROTO-ONCOGENES;

EID: 33644848504     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Baldi A., Esposito V., De Luca A., Howard C.M., Mazzarella G., Baldi F., Caputi M. and Giordano A. (1996). Differential expression of the retinoblastoma gene family members pRb/pIOS, p107 and pRb2/pl3O in lung cancer. Clin. Cancer Res. 2, 1239-1245.
2. Baldi A., Esposito V., De Luca A., Fu Y., Meoli I., Giordano G.G., Caputi M., Baldi F. and Giordano A. (1997). Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin. Rev. Res. 3, 1691-1697.
3. Baldin V., Lukas J., Marcote M.J., Pagano M. and Draetta G. (1993). Ciclin D is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7, 812-821.
4. Baserga R. and Rubin R. (1993). Cell cycle and growth control. Crit. Rev. Eu. Gene. Ex. 3, 47-61.
5. Bates S., Bonetta L., MacAllan D., Parry D., Holder A., Dickson C. and Peters G. (1994). CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin dependent kinase that associate with cyclin D1. Oncogene 9, 71-79.
6. Bookstein R., Rio P., Madreperla S.A., Hong F., Allred C., Grizzle W.E. and Lee W.H. (1990). Promoter deletion and loss of retinoblastoma gene in human prostate carcinoma. Proc. Natl. Acad. Sci. USA 87, 7762-7766.
7. Cavenee W.K., Hansen M.F., Nordenskjold M., Kock E., Maumenee I., Squire J., Philips R.A. and Gallie B.L. (1985). Genetic origin of mutations predisposing to retinoblastoma. Science 228, 501-503.
8. Chittenden T., Livingston D.M. and Kaelin W.G. Jr (1991). The T/EIA - binding domain of the retinoblastoma product can interact selectively with a sequence-specific-DNA binding protein. Cell 65, 1073-1082.
9. Claudio P.P., Howard C.M., Baldi A., De Luca A., Fu Y., Condorelli G., Sun Y., Colburn N., Calabretta B. and Giordano A. (1994). pRb2/pI3O has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res. 54, 5556-5560.
10. Cordon Cardo C. (1995). Mutation of the cell cycle regulators: biological and clinical implication for human neoplasia. Am. J. Pathol. 147, 545-560.
11. DeCaprio J A., Ludlow J.W., Lynch D., Furukawa Y., Griffin J., Piwnica-Worms H., Huang C.M. and Livingstone D.M. (1 989). The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58, 1085-1095.
12. DeCaprio J.A., Ludlow J.W., Figge J., Shew J.Y. Huang C.M., Lee W.H., Marsilio E., Paucha E and Livingstone D.M. (1988). SV40 large tumor antigens forms a specific complex with the product of the retinoblastoma. susceptibility gene. Cell 54, 275-283.
13. De Marini D.M. (1993). Genotoxicity of tobacco smoke and tobacco smoke condensate. Mutat. Res. 114, 447-474.
14. Deb S., Jackson C.T., Subler M.A. and Martin D.W. (1994). Modulation of cellular and viral promoters by mutant human P53 proteins was found in tumor cells. J. Virol. 66, 6164-6170.
15. Deb S.P, Munoz R.M., Brown D.R., Subler M.A. and Deb S. (1994). Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9, 1341-1349.
16. Dosaka-Akita H., Shindoh M., Fujino M., Kinoshita I., Akie K., Katoh M. and Kawakami J. (1994). Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am. J. Clin. Pathol. 102, 660-664.
17. Dowdy S.F., Hinds P.W., Louie K., Reed S.J., Arnold A. and Weinberg R.A. (1993). Phisical interaction of the retinoblastoma protein and human D cyclins. Cell 73, 499-511.
18. Downes C.S. and Wilkins A.S. (1994). Cell cycle checkpoints, DNA repair and DNA replication strategies. Bioessays 16, 75-79.
19. Draetta G. and Beach D. (1988). Activation of cdc2 protein kinase during mitosis in human cells: cell cycle dependent phosphorilation and sub-unit rearrangement. Cell 54, 17-26.
20. Draetta G., Luca F., Westendorf J., Brizuela L., Ruderman J. and Beach D. (1989). Cdc2 protein kinase is complexed with both cyclin A and B: evidence for proteolitic inactivation of MPF. Cell 56, 829-838.
21. Durfee T., Becherer K., Chen P.L., Yeh S.H., Yang Y., Kilburn A.E., Lee W.H. and Elledge D.S. (1993). The retinoblastoma protein associates with the protein phosphatase type-1 catalytic subunit. Genes Dev. 7, 555-569.
22. Ebina M., Steinberg S.M., Mulshine J.L. and Linnoila I. (1994). Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non small cell lung cancer. Cancer Res. 54, 2496-2503.
23. Eliyahu D., Raz A., Gruss P., Givol D. and Oren M. (1984). Participation of p53 tumor cellular antigen in transformation of normal embrionic cells. Nature 312, 646-649.
24. Esposito V., Baldi A., De Luca A., Groger A., Giordano G.G., Caputi M., Baldi F., Pagano M. and Giordano A. (1997). Prognostic role of the cyclin-dependent kinase inhibitor p27 in non small cell lung cancer. Cancer Res. 57, 3381-3385.
25. Esposito V., Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F, Caputi M and Giordano A. (1997). Prognostic value of p53 in nonsmall cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol. 28, 233-237.
26. Esposito V., Baldi A., Tonini G., Santini M., Ambrogi V., Persichetti P., Meneo T.C., Baldi F. and Groeger A.M. (2004). Analysis of cell cylce regulator proteins in non-small cell lung cancer. J. Clin. Pathol. 57, 58-63.
27. Esposito V., Baldi A., De Luca A., Tonini G., Vncenzi B., Santini D., Persichetti P., Mancini A., Citro G., Baldi F., Groeger A.M. and Caputi M. (2005). Cell cycle related proteins as prognostic parameters in radically resected non small cell lung cancer (NSCLL). J. Clin. Pathol. 58, 734-739.
28. Ewen M.E., Sluss H.K., Sherr C.J., Matsushime H., Ka U-J. and Livingstone D.M. (1993). Functional interactions between the retinoblastoma protein with mammalian D-type cyclins. Cell 73, 487-497.
29. Ewen M.E., Xing Y., Lawrence J.B. and Livingstone D.M. (1991). Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66, 1155-1164.
30. Fang F. and Newport J.W. (1991). Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eucaryotes. Cell 66, 731-742.
31. Fields S. and Jang S.K. (1990). Presence of a potent transcription activating sequence in the pS3 protein. Science 249, 1046-1049.
32. Flores-Rozas H., Kelman Z., Dean T.B. Pan Z.Q., Harper J.W., Elledge S.J., O'Donnell M. and Huwitz J. (1994). Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA 91, 8655-8659.
33. Fontanini G., Bigini D., Vignati S., Macchiarini P., Pepe S., Angeletti C.A., Pingitore R. and Squartini F. (1993). P53 expressions in non small cell lung cancer: Clinical and biological correlations. Anticancer Res. 13, 737-742.
34. Fontanini G., Macchiarini P., Pepe S, Ruggiero H., Hardin M., Bigini D., Vignati S., Pingitore R. and Angeleiti C.A. (1992). The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node negative, NSCLC. Cancer 70, 152-157.
35. Fontanini G., Vignati S., Bigini D., Merlo G.R., Ribecchini A., Angeletti C.A., Basolo F., Pingitore R. and Bevilacqua G. (1994). Human non small cell lung cancer: p53 protein accumulation is an early event and persist during metastatic progression. J. Pathol. 174, 23-31.
36. Fornace A.L. Jr, Nebert D.W., Hollander M.C., Luenthy J.D., Papathanasiou M., Fargnoli J. and Holbrook N.J. (1989). Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell. Biol. 9, 4196-4203.
37. Forrester K., Lupold S.E., Ott V.L. ChEiy C.H., Band V., Wang X.W. and Harris C.C. (1995). Effects of p53 mutants on wild type P53-mediated transactivation are cell type dependent. Oncogene 10, 2103-2111.
38. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M. and Dryja T.P. (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643-646.
39. Friend S.H., Horowitz J.M., Gerber M.R., Wang X.F., Bogenmann E., Li F.P. and Weinberg R.A. (1987). Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc. Natl. Acad. Sci. USA 84, 9059-9063.
40. Fujino M., Dosaka-Akita H., Harada M., Hiroumi H., Kinoshita I., Akie K. and Kawakami Y. (1995). Prognostic significance of p53 and ras p2I expression in non small cell lung cancer. Cancer 76, 2457-2463.
41. Fung Y.K., Murphree A.L., T'Ang A., Quian J., Hinrichs S.H. and Benedict W.F. (1987). Structural evidence for the autenticity of the human retinoblastoma gene. Science 236, 1657-1661.
42. Geradts J., Kratzke R.A., Niehans G.A and Lincoln C.E. (1995). Immunohistohemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16ink4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 55, 6006-6011.
43. Godbout R., Dryja T.P., Squire J., Gallie B.L. and Phillips R.A. (1983). Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 304, 451-453.
44. Goodrich D.W., Wang N.P., Quian Y.W., Lee E.Y. and Lee W.H. (1991). The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67, 293-302.
45. Greenblatt M.S., Bennett W.P., Hollstein M. and Harris C.C. (1994). Mutations in the p53 tumor suppessor gene. clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
46. Groeger A.M., Esposito V., De Luca A., Lassandro R., Tonini G., Ambrosi V., Baldi F., Goldfarb R., Mineo T.C., Baldi A., Wolner E. (2004). Prognostic value of immunohistochemical expression of p53, BAX, Bcl-2 and Bcl-X1 in resected non small cell lung cancer. Histopathology 44, 54-63.
47. Harbour J.W., Lai S.L., Whang-Peng J., Gazdar A.F., Minna J.D. and Kaye F.J. (1988). Abnormalities in structure and expression of the human retinoblastoma gene in SCILC. Science 241, 353-357.
48. Harper J.W., Adami G.R., Wei N., Keiomarski K. and Elledge S.J. (1993). The p2I cdk-interacting protein CIP1 is a potent inhibitor of G1 cyclin dependet kinases. Cell 75, 805-816.
49. Hensel C.H., Hsieh C.L., Gadzar A.F., Johnson B.E., Sakaguchi A.Y., Naylor S.L., Lee W.H. and Lee E.Y. (1990). Altered structure and expression of the human retinoblastoma gene in small cell lung cancer. Cancer Res. 50, 3067-3072.
50. Higashiyama M., Doi O., Kodama K., Yokouchi H. and Tateishi R. (1994). Retinoblastoma protein in lung cancer. and immunohistochemical analysis. Oncology 51, 544-551.
51. Hollstein M., Sidransky D., Vogelstein B. and Harris C.C. (1991). P53 mutations in human cancers. Science 25, 49-53.
52. Horowitz J.M., Yandell D.W., Park S.H., Canning S., Whyte P., Buchkovich K., Arlow E., Weinberg R.A. and Dryja T.P. (1989). Point mutational inactivation of the retinoblastoma antioncogene. Science 243, 937-940.
53. Huang H.J., Yee J.K., Shew J.Y. and Chen P.L. (1988). Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242, 1563-1566.
54. Iggo R., Gatter K., Bartek J., Lane D. and Harris A.L. (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 535, 675-659.
55. Inaba T., Matsushime H., Valentine M., Roussel M.F., Sherr C.J. and Look A.T. (1992). Genomic organization, cromosomal localization, and independent exprssion of human cyclin D genes. Genomics 13, 565-574.
56. Jenkins J.R., Rudge K. and Currie G.A. (1984). Cellular immortalization by a cDNA clone encoding the transformation associated phosphoprotein p53. Nature 312, 651-654.
57. Johnson D.J., Schwartz J.K., Cress W.D. and Nevins J.P. (1993). Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365, 349-352.
58. Kaelin W.G. Jr, Pallas D.C., DeCaprio J.A., Kaye F.J. and Livingston D.M. (1991). Identification of cellular proteins that can interact specifically with the T/EIA-binding region of the retinoblastoma gene product. Cell 64, 521-532.
59. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B. and Craig R.W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51 (23 Pt 1), 6304-6311.
60. Kato J., Matsushime H., Hiebert S.W., Ewen M.E. and Sherr C.J. (1993). Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorilation by the cyclin dependent kinase CDKs. Genes Dev. 7, 331-342.
61. Kaye F.J., Kratzke R.A., Gerster J.L. and Horowitz J.M. (1990). A single aminoacid substitution results in a retinoblastorna, protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87, 6922-6926.
62. Kitagawa M., Higashi H., Takahashi I.S., Okabe T., Ogino H., Taya Y., Hishimura S. and Okuyama A. (1994). A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9, 2549-2557.
63. Knoblich J.A., Sauer K., Jones L., Richardson H., Saint R. and Lehner C.F. (1994). Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell 77, 107-120.
64. Knudson A.G. Jr (1971). Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68, 820-823.
65. Knudson A.G. Jr (1978). Retinoblastoma: a prototypic hereditary neoplasm. Semin. Oncol. 5, 57-60.
66. Koff A., Cross F., Fisher A., Shumacher J., Leguellec K., Philippe M. and Roberts J.M. (1991). Human cyclin E, a new cyclin that interacts with two members of the cdc2 gene family. Cell 66, 1217-12228.
67. Koff A., Giordano A., Desai D., Yamashita K., Harper J.W. , Helledge S., Nishimoto T., Morgan D.O., Franza B.R. and Roberts J.M. (1992). Formation and activation of a cyclin E cdk2 complex during the G1 phase of the cell cycle. Science 257, 1689-1694.
68. La Vecchia C. and Levi F. (2003). Lung cancer in Europe: the levelling of an epidemic. Eur. J. Public Health 13, 1-2.
69. Lee J.S., Yoon A. and Kalapurakal S.K. (1995). Expression of p53 oncoprotein in non small cell lung cancer: a favorable prognostic factor. J. Clin. Oncol. 13, 1893-18903.
70. Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y. and Lee E.Y. (1987). Human retinoblastoma susceptibility gene, cloning, identification, and sequence. Science 235, 1394-1399.
71. Li R., Waga S., Shannon G.J., Beach D. and Stillman B. (1994). Differential effects by the p2I CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371, 534-537.
72. MacLachlan T.K., Sang N. and Giordano A. (1995). Cyclins, Cyclin-dependent Kinases and Cdk inhibitors: Implication in cell cycle control and cancer. Crit. Rev. Eucar Gene Express. 5, 127-156.
73. Marshall C.J. (1994). MAP Kinase Kinase Kinase, MAP kinase kinase and MAP Kinase . Curr. Op. Genet. Dev. 4, 82-89.
74. Mayol X., Grana X., Baldi A., Sang N., Hu Q. and Giordano A. (1993). Cloning a new member of the retinoblastoma gene family (pRb2) which binds to the EIA tranforming domain. Oncogene 8, 2561-2566.
75. Mercer W.E., Shields M.T., Amin M., Sauve G.J., Appella T., Romano J.V. and Ullrich S.J. (1990). Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild type p53. Proc. Natl. Acad. Sci. USA 87, 6166-61670.
76. Minna J.D. (1993). The molecular biology of lung cancer pathogenesis. Chest. 103, 449S-456S.
77. Minna K.D., Maneckjee R. and D'Amico D. (1991). Mutations in dominant and recessive oncogenes, and the expression of opioid and nicotine receptors in the pathogenesis of lung cancer. In: Origins of human cancer: a comprehensive review. Harlow E. ed. Cold Spring Harbor Press, Cold Spring Harbor, New York. 781-789.
78. Mittnacht S. and Weinberg R.A. (1991). GI/S phosphorilation of the retinoblastoma protein is associated with an altered affinity for the nuclear component. Cell 65, 381-393.
79. Montenarh M. (1992). Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 7, 673-680.
80. Moran E. (1993). DNA tumor virus transforriing protein and the cell-cycle. Curr. Opin. Genet. Dev. 3, 63-70.
81. Mori N., Yokota J., Akiyama T., Sameshima Y., Okamoto A., Mizoquchi H., Toyoshima K., Sugimura T. and Terada M. (1990). Vaariable mutation of the RB gene in small cell lung carcinoma. Oncogene 5, 1713-1717.
82. Murray A.W. (1994). Cyclin-dependent kinases: regulators of the cell cycle and more. Chem. Biol. 1, 191-195.
83. Murray A.W. and Hunt T. (1993). The cell cycle, an introduction. New York. Freeman ed.
84. O'Connell M.J. and Nurse P. (1994). How cells know they are in G-1 or G2. Curr. Op. Cell. Biol. 6, 867-871.
85. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L. and Vogelstein B. (1992). Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 358, 80-83.
86. Pagano M., Pepperkok R., Verde F., Ansorge V. and Draetta G. (1992). Cyclin A is required at two points in the human cell. cycle. EMBO J. 11, 961-971.
87. Parry D., Bates S., Mann D.J. and Peters H. (1995). Lack of cyclin D-cdk complexes in rb-negative cells correlates with high levels of p161 nk4/MTS1 tumor suppressor gene product. EMBO J. 14, 503-511.
88. Puisieux A., Lim S., Groopman J. and Ozturk M. (1991). Selective targeting of p53 gene mutatiomal hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51, 6185-6189.
89. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E. and Doshi H.M. (1992). Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52, 4828-48231.
90. Ramael M., Jacobs W., Weyler J. Van Meerbeeck J., Bialasiewicz P., Van den Bossche J., Buysse C., Vermeire P. and Van Marck E. (1994). Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J. Pathol. 172, 247-253.
91. Reissmann P.T., Koga H., Takahashi R., Figlin R.A., Holmes E.C., Piantadosi S., Cordon-Cardo C. and Slamon D.J. (1993). Inactivation of the retiniblastoma suscepitibility gene in non small cell lung cancer. The Lung Cancer Study Group. Oncogene 8, 1913-1919.
92. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., Hong W.K., Komaki R., Lee J.J., Nesbitt J.C., Pisters K.M., Putnam J.B., Schea R., Shin D.M., Walsh G.L., Dolormente M.M., Han C.I., Martin F.D., Yen N., Xu K., Stephens L.C., McDonnell T.J., Mukhopadhyay T. and Cai D. (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2, 985-991.
93. Sachse R., Murakami Y., Shiraishi M., Hayashi K. and Sekiya T. (1994). DNA aberration at the retinoblastoma locus in human squamous cell carcinomas of the lung. Oncogene 9, 39-47.
94. Sager R. (1985). Genetic suppression of tumor formation. Adv. Cancer Res. 44, 43-68.
95. Sang N., Avvantaggiati M.L. and Giordano A. (1997). Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. J. Cell. Biochem. 66, 277-285.
96. Selvakumaran M., Lin H., Miyashita T., Wang H.G., Krajewski S., Reed J.C., Hoffman B. and Liebermann D.A. (1994). Immediate early regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798.
97. Serrano M., Hannon G.J. and Beach D (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707.
98. Shirodkar S., Ewen M., De Caprio K.A., Morgan J., Livingstone D.M. and Chittenden T. (1992). The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle regulated manner. Cell, 68, 157-166.
99. Shottenfeld D. (1996). Epidemiology of lung cancer. In: Lung cancer principles and practice. Pass H.I., Mitchell J.B. Johnson H. and Turrisi A.T. (eds). Lippincott-Raven pubblishers. Philadelpia.
100. Sporn M.B. and Roberts A.D. (1985). Autocrine growth factors and cancer. Nature 313, 745.
101. Stoker M. (1967). Contact and short-range interactions affecting growth of animals cells in culture. Curr. Top. Dev. Biol. 2, 107-128.
102. Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y. and Ueda R. (1992). p53 mutations in non small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 52, 734-736.
103. Vairo G., Livingston D.M. and Ginsberg D. (1995). Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underllying growwth suppression by different retinoblastoma protein family members. Genes Dev. 9, 869-881.
104. Van den Heuvel S. and Harlow E. (2005). Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-2054.
105. Vogelstein B. and Kinzler K.W. (1992). P53 functions and disfunctions. Cell 70, 523-526.
106. Waga S., Hannon G.J., Beach D. and Stillman B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication with PCNA. Nature 369, 574-578.
107. Weinberg R.A. (1991). Tumor suppressor genes. Science 254, 1138-1146.
108. Wynford-Thomas D. (1991). Oncogenes and anti-oncogenes; the molecular basis of tumor behavior. J. Pathol. 165, 187-201.
109. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R. and Livingston D.M. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375, 694-698.
110. Xiong Y., Connolly T., Futcher B. and Beach D. (1991). Human D-type cyclins. Cell. 65, 691-699.
111. Xiong Y., Zhang H. and Beach D. (1992). D type cyclins associte with multiple protein kinases and the replication factor PCNA. Cell 71, 505-514.
112. Xiong Y, Hannon G.J., Zhang H., Casso D., Kobayashi R. and Beach D. (1993). p2I is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
113. Xu H.J., Hu S.X., Cagle P.T., Moore G.E. and Benedict W.F. (1991). Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. 51, 2735-2739.
114. Yokota J., Wada M., Shimosato Y., Terada M. and Sugimura T. (1987). Loss of heterozygosity on chromosomes 3, 13, and 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl. Acad. Sci. USA 84, 9252-9256.
115. Zhang H., Xiong Y. and Beach D. (1993). Proliferating cell nuclear antigen and p2I are components of multiple cell cycle kinase complexes. Mol. Biol. Cell. 4, 897-906.
116. Zhu L., Van Den Heuvel S., Helin K., Fattaey A., Ewa T.M., Livingston D.M., Dyson N. and Harlow E. (1993). Inhibition of cell proliferation by p107, a relative of the retinoblastoma-protein. Genes Dev. 7, 1111-1125.